BCL3 is a proto-oncogene affected by chromosomal translocations in some patients with chronic lymphocytic leukemia. It is an IjB family protein that is involved in transcriptional regulation of a number of NF-jB target genes. In this study, interleukin (IL)-6-induced BCL3 expression and its effect on survival of multiple myeloma (MM) cells were examined. We demonstrate the upregulation of BCL3 by IL-6 in INA-6 and other MM cell lines. Sequence analysis of the BCL3 gene locus revealed four potential signal transducer and activator of transcription (Stat) binding sites within two conserved intronic enhancers regions: one located within enhancer HS3 and three within HS4. Chromatin immunoprecipitation experiments showed increased Stat3 binding to both enhancers upon IL-6 stimulation. Silencing Stat3 expression by small interfering RNA (siRNA) abrogated BCL3 expression by IL-6. Using reporter gene assays, we demonstrate that BCL3 transcription depends on HS4. Mutation of the Stat motifs within HS4 abolished IL-6-dependent BCL3 induction. Furthermore, BCL3 transcription was inhibited by its own gene product. This repressive feedback is mediated by NF-jB sites within the promoter and HS3. Finally, we show that overexpression of BCL3 increases apoptosis, whereas BCL3-specific siRNA does not affect the viability of INA-6 cells suggesting that BCL3 is not essential for the survival of these cells.
Introduction
Multiple myeloma (MM) is a B-cell neoplasm characterized by the accumulation of clonal malignant plasma cells within the bone marrow. Interleukin (IL)-6 is known to play an essential role in the proliferation and survival of MM cells (Klein et al., 1995) . In the human IL-6-dependent MM cell line INA-6 (Burger et al., 2001) , we recently demonstrated that IL-6 promotes survival through an as yet unknown antiapoptotic pathway that required the activation of signal transducer and activator of transcription 3 (Stat3) (Brocke-Heidrich et al., 2004) .
When comparing the gene expression profiles of INA-6 cells grown in the presence or absence of IL-6, we observed the induction of BCL3 (Brocke-Heidrich et al., 2004) , originally identified as a candidate protooncogene overexpressed in certain cases of B-cell chronic lymphocytic leukemia as a consequence of a t(14;19) chromosomal translocation Ohno et al., 1990) . High BCL3 expression has also been reported in a subgroup of anaplastic large-cell lymphoma (Nishikori et al., 2003) . Consistent with an oncogenic function, BCL3 can directly transform cells and induce tumor growth in vivo (Viatour et al., 2004) . Furthermore, BCL3 has been suggested to be involved in the pathogenesis of solid tumors such as nasopharyngeal carcinoma (Thornburg et al., 2003) and breast cancer (Cogswell et al., 2000) .
BCL3 belongs to the IkB family of proteins , which contain an ankyrin repeat domain through which they interact with, and modulate the activity of NF-kB transcription factors. In mammals, there are five members of the NF-kB family: RelA (p65), RelB, c-Rel, p50 and p52, forming various homo-and heterodimers. The prototypical form of NF-kB is a heterodimer of p50 and p65. BCL3 is mainly located in the nucleus and regulates NF-kB transcriptional activity Nolan et al., 1993) . By forming complexes with p50 and p52 homodimers, it can either activate Fujita et al., 1993) or repress (Kerr et al., 1992; Wulczyn et al., 1992; Kuwata et al., 2003) gene transcription. Furthermore, phosphorylation plays an important role in regulating the transcriptional function of BCL3 Bundy and McKeithan, 1997) . Thus, BCL3 overexpression is proposed to cause dysregulation of genes normally regulated by NF-kB transcription factors implicated in cell proliferation, apoptosis and differentiation .
The transcription of BCL3 is regulated through several signalling pathways. It is itself an NF-kB target gene whose expression is induced by a number of classic NF-kB-inducing stimuli such as tumor necrosis factor-a (TNF-a) (Brasier et al., 2001) or IL-1 (Elliott et al., 2002) . Although IL-4 promotes BCL3 transcription in T cells through an AP-1-dependent mechanism (Rebollo et al., 2000) , IL-9 was reported to induce BCL3 expression through the Jak/Stat pathway (Richard et al., 1999) .
Given the oncogenic potential of BCL3, we investigated the transcriptional regulation of BCL3 by IL-6 and the effect of its expression on survival of the IL-6-dependent MM cell line INA-6. Using chromatin immunoprecipitation (ChIP), RNA interference and reporter gene assays, we show that IL-6-induced BCL3 expression is mediated through Stat3 binding to the intronic enhancer HS4. Additionally, BCL3 transcription is negatively regulated by its own gene product. Finally, we found that BCL3 is not required for survival of MM cell line INA-6.
Results

BCL3 expression is induced by IL-6 in MM cell lines
Among the IL-6 target genes potentially involved in the pathogenesis of MM identified by microarray analysis of INA-6 cells was the BCL3 gene (Brocke-Heidrich et al., 2004) , whose induction was confirmed by real-time PCR at different time points upon IL-6 treatment ( Figure 1a) .
Next, we analysed BCL3 protein expression in INA-6 cells after IL-6 stimulation ( Figure 1b) . Before IL-6 treatment little BCL3 was detected. Exposure to IL-6 permanently increased BCL3 expression after an initial delay, reaching maximal induction after about 8 h. At least four distinct forms of BCL3 (as indicated by arrows) were observed, most likely reflecting different phosphorylation states of the protein as described Bundy and McKeithan, 1997) . To study whether the BCL3 induction by IL-6 is a common feature of MM cell lines, we further analysed cell lysates from JK6-E, XG-1 and MM1.S cells cultured in the presence or absence of IL-6. The immunoblot revealed a strong BCL3 upregulation in all IL-6-treated samples (Figure 1c ). In contrast, BCL3 levels in IL-6-responsive HepG2 hepatocellular carcinoma cells did not change in response to IL-6.
IL-6 initiates Stat3 binding to intronic enhancers of the BCL3 gene
Recently, we showed that regulation of most IL-6 target genes in INA-6 cells requires Stat3 activation (BrockeHeidrich et al., 2004) . Sequence analysis of the BCL3 gene locus revealed four potential Stat binding sites within the evolutionarily conserved regions described previously. In addition to cis-regulatory elements of the BCL3 promoter (Rebollo et al., 2000; Brasier et al., 2001) , two downstream enhancers within intron 2 (named HS3 and HS4) have been identified by phylogenetic footprint analysis and DNase hypersensitivity assays (Ge et al., 2003) . One of the Stat motifs is located within HS3 and three within HS4 (Figure 2a) .
To examine whether Stat3 binds to the BCL3 enhancers, IL-6-starved INA-6 cells were restimulated, and samples taken at different time points were subjected to a ChIP assay (Figure 2b) . Results indicate that Stat3 was permanently recruited to both HS3 and HS4 upon IL-6 stimulation. The strongest DNA binding was detected after 30 min. To ask whether the lack of BCL3 induction in HepG2 cells is owing to a failure of Stat3 to bind the enhancers in these cells, we also performed ChIP assays (data not shown). Enhanced Stat3 accumulation was observed on both enhancer regions 30 min after IL-6 treatment. Thus, both HS3 and HS4 are accessible for Stat3 in HepG2 cells as well.
Next, we tested whether a knock down of Stat3 affects BCL3 protein expression. To this purpose, Stat3-specific small interfering RNA (siStat3) was expressed in INA-6 and XG-1 cells in the presence of IL-6. Downregulation of Stat3 led to reduced BCL3 protein levels compared to control cells expressing a scrambled sequence (Figure 2c ), demonstrating a pivotal role for Stat3 in IL-6-induced BCL3 expression.
To further confirm the initiation of BCL3 gene transcription by Stat3 activation, we checked whether a luciferase reporter construct driven by the BCL3 promoter and both enhancer regions (HS3/4) can respond to IL-6. Initial experiments showed that this construct is strongly activated by IL-6 in INA-6 cells (not shown, and see below). When the reporter gene assay was performed in HepG2 cells, a 10-fold induction of luciferase activity was detected despite the lack of IL-6-induced BCL3 expression in these cells ( Figure 2d ). As INA-6 cells are difficult to manipulate, reporter gene assays in HepG2 cells provide a convenient system to study BCL3 gene transcription by IL-6. Expression of siStat3 reduced IL-6-mediated HS3/4 luciferase activity to 30% (Figure 2d ).
To determine whether the four potential Stat binding sites are involved in IL-6-induced transcription of BCL3, site-directed mutagenesis within the identified motifs was performed. Wild-type HS3/4 and mutated variants were subjected to reporter gene analysis in HepG2 cells (Figure 2e ). Mutating any one of the putative Stat binding sites decreased HS3/4 activity upon IL-6 addition, indicating that all four Stat binding motifs contribute to the IL-6-induced BCL3 transcription, although to a different extent. However, mutation of the three Stat motifs within HS4 together abolished reporter gene activity to almost the same extend as did the combined mutation of all Stat sites. Thus, although the Stat-binding motif in HS3 seems to be functional, Stat sites in HS4 are essential for BCL3 reporter activity in response to IL-6.
IL-6 initiates BCL3 transcription through enhancer HS4
We next tested whether IL-6-induced BCL3 transcription is indeed mediated by HS4 in HepG2 and INA-6 cells. For this purpose, we analysed luciferase activity of reporter constructs containing the BCL3 promoter either alone or together with enhancer HS3 and/or HS4 ( Figure 3a ). Little (HepG2; Figure 3b ) or no (INA-6; Figure 3c ) stimulation by IL-6 was found with the promoter and HS3 construct. As expected, IL-6 addition caused a marked increase of luciferase activity with HS4 in both cell types. Thus, reporter gene assays suggest a primary role for enhancer HS4 in IL-6-induced BCL3 transcription. Interestingly, the luciferase construct containing HS3 and HS4 behaved differently in hepatocellular carcinoma and myeloma cells. Whereas IL-6 treatment led to a similar stimulation of HS4 and HS3/4 in HepG2 cells, HS3/4 activity was significantly reduced compared to HS4 in INA-6 cells. Apparently, the decreased reporter activity of HS3/4 in INA-6 cells is owing to HS3, which is known to contain an NF-kB site (Ge et al., 2003) . Elimination of this NF-kB site by point mutation reconstituted HS3/4 activity ( Figure 3c , lower column), suggesting that BCL3 expression is negatively regulated through this site. As BCL3 was detected in INA-6 but not in HepG2 cells (Figure 1 ), this result raised the possibility that BCL3 represses its own transcription in an NF-kB dependent manner. Transcriptional regulation of BCL3 by IL-6 K Brocke-Heidrich et al BCL3 transcription is negatively regulated by its own gene product To verify the putative influence of BCL3 on its own transcription, BCL3 was co-expressed with reporter genes in HepG2 cells. As BCL3 was recently described to inhibit the Stat pathway (Jamaluddin et al., 2005) , the effect of increasing amounts of BCL3 expression plasmid on HS3/4 reporter was compared with the one on the known Stat3-dependent promoters of a 1 -antichymotrypsin (ACT, Figure 4a ) and suppressor of cytokine signalling 3 (SOCS3, not shown). 250 ng of the BCL3 expression plasmid driven by the murine leukemia virus (MLV) promoter reduced BCL3 promoter/enhancer activity to about 30%, whereas no significant effect was seen on the ACT and SOCS3 promoter up to 1 mg. However, repression of ACT and SOCS3 promoter activity was observed when using 250 ng of a BCL3 expression plasmid under the control of the stronger cytomegalovirus promoter (not shown). Thus, the repressive action of BCL3 on its own transcription occurs at lower concentration than required to inhibit the Stat3 pathway.
To identify the regulatory regions involved in this negative feedback, we analysed the effect of BCL3 expression on the BCL3 promoter either alone or in combination with either HS3 or HS4. The activities of all three constructs were downregulated by BCL3 expression (Figure 4b ), apparently through NF-kB binding sites within the promoter. To further determine the contribution of HS3 and HS4 to the observed negative feedback, luciferase constructs were used that contain the core promoter from the herpes simplex thymidine kinase (TK) gene with or without the HS3 and HS4 region. BCL3 expression did not influence the TK promoter either alone or in combination with HS4 ( Figure 4c ). In contrast, the activity of the TK promoter together with HS3 was decreased by BCL3.
BCL3 is known to regulate transcription through the association with DNA-bound p50 homodimers. The presence of both p50 and BCL3 on HS3 enhancer in INA-6 cells was proven by ChIP assay (Figure 4d ) and occurred in both the presence and absence of IL-6 (not shown). These results strongly suggest that BCL3 represses its own transcription in a very sensitive manner by forming a complex with p50 at NF-kB sites within the BCL3 promoter and HS3.
Ectopic expression of BCL3 reduces survival of myeloma cell line INA-6 We next addressed the question whether the induction of BCL3 can account for the IL-6-mediated survival of INA-6 cells. For this purpose, BCL3 was stably overexpressed by using a lentiviral vector allowing coexpression with enhanced green fluorescent protein (EGFP) through an IRES sequence. A lentiviral vector expressing only EGFP was used as a control (Figure 5a ). Apoptosis of EGFP-positive cells cultured in either the presence or absence of IL-6 was determined (Figure 5b ). Ectopic expression of BCL3 reduced the number of viable cells with and without IL-6 to 75%. Thus, forced BCL3 expression decreased survival of myeloma cell line INA-6.
To further clarify whether INA-6 cells require BCL3 for survival, we applied siRNA specifically targeting BCL3 mRNA. The results showed that downregulation of BCL-3 did not affect survival of INA-6 cells (data not shown).
Discussion
In a previous study, we identified the proto-oncogene BCL3 as an IL-6 target gene (Brocke-Heidrich et al., 2004) . Here, we show that IL-6 induces BCL3 expression in myeloma cells but not in hepatocellular carcinoma cells. The BCL3 induction requires Stat3 activity. This result is consistent with our previous study revealing that transcriptional regulation of the vast majority of IL-6 target genes in INA-6 cells required Stat3 activation (Brocke-Heidrich et al., 2004) . Richard et al. (1999) reported that BCL3 induction in mast and T cells upon IL-9 stimulation depends on the Jak/Stat pathway. They suggested a pivotal role for Stat3. Furthermore, IL-10, also known to signal primarily via Stat3 activation, was found to induce BCL3 expression in macrophages (Kuwata et al., 2003) . As we show here, Stat3 initiates transcription through binding to BCL3 enhancers. A regulatory sequence within intron 2 consisting of two separate evolutionarily conserved and DNase-hypersensitive regions corresponds to enhancers HS3 and HS4. Although HS3 was found to be responsible for NF-kB-induced upregulation of BCL3 by TCR-mimetic signals (Ge et al., 2003) , the role of HS4 remained unclear. Concluding from our reporter gene assays, HS4 has the potential to act as a strong IL-6-responsive enhancer also in vivo. The single Stat binding site in HS3 was not sufficient for BCL3 induction, suggesting that binding of Stat3 to the three motifs within HS4 is essential. ChIP and reporter gene assays indicated that all known requirements for transcriptional initiation in HepG2 cells were fulfilled. Thus, the question arises why IL-6 does not induce BCL3 protein expression in HepG2 cells. Among the possible explanations are epigenetic alterations of the gene locus in HepG2 cells or mRNA instability. The induction of IkB-z, a close relative of BCL3, requires activation by NF-kB and stimulus-specific stabilization of its mRNA (Yamazaki et al., 2005) . Assuming a similar mechanism for BCL3, both NF-kB and Stat3 can activate transcription, but only NF-kB additionally stabilizes BCL3 mRNA. MM cells show sustained NF-kB activation (Feinman et al., 1999) . Thus, in contrast to HepG2 cells, a low level of activated NF-kB may stabilize IL-6-induced BCL3 mRNA in INA-6 cells.
BCL3 can either stimulate or inhibit NF-kB-dependent transcription (Kerr et al., 1992; Wulczyn et al., 1992; Franzoso et al., 1993; Fujita et al., 1993; Kuwata et al., 2003) . Consistent with the observation that many transcription factors are auto-regulated (Angel et al., 1988; Chen et al., 1995) , our data demonstrate that BCL3 negatively regulates its own transcription. Testing dissected promoter/enhancer luciferase constructs revealed that the negative feedback is mediated by the BCL3 promoter and HS3. Both regions have been reported to possess NF-kB binding sites. Within the BCL3 promoter, two high-affinity NF-kB motifs have been described, located at À872 to À861 and À106 to À96 nt. The latter has been shown to mediate the Transcriptional regulation of BCL3 by IL-6 K Brocke-Heidrich et al upregulation of BCL3 upon TNF-a stimulation in HepG2 cells (Brasier et al., 2001 ). As mentioned above, the NF-kB site within HS3 was shown to be targeted by stimuli that mimic TCR activation, such as phythaemagglutinin (PHA) and phorbol 12-myristate 13-acetate (PMA). In addition, both the BCL3 promoter and HS3 were found to respond to ectopic expression of NF-kB subunits p50 and p65 (Ge et al., 2003) . An NF-kB site able to mediate both negative and positive transcriptional effects by a p50/BCL3-containing complex was reported for the KAI1 gene (Baek et al., 2002) . We show that mutating the NF-kB site within HS3 abolished the repressive effect seen on the HS3/4 luciferase construct in INA-6 cells. This finding confirmed that repression of BCL3 transcription is mediated through NF-kB binding motifs. BCL3 exerts its function through binding to NFkB p50 homodimers (Inoue et al., 1993) . In line with these findings, our ChIP results show simultaneous binding of p50 and BCL3 to enhancer HS3. Thus, the negative auto-regulation of BCL3 is likely mediated by its interaction with p50 bound to NF-kB sites in the promoter and HS3. Furthermore, even at the low BCL3 protein levels in the absence of IL-6 we observe BCL3 binding to the HS3 enhancer. Hence, we believe that the function of the negative feedback is to tightly control both BCL3 basal expression and to limit its induction amplitude.
Recent findings have correlated BCL3 expression with increased cellular proliferation and survival in lymphocytes (Ong et al., 1998; Rebollo et al., 2000; Mitchell et al., 2001) . Thus, we speculated that upregulation of BCL3 could contribute to the IL-6-mediated antiapoptotic effect in MM cells. However, ectopic expression of BCL3 in myeloma cell line INA-6 did not enhance but instead decreased survival in both the presence and absence of IL-6. Obviously, BCL3 negatively modulated survival genes in INA-6 cells. We cannot rule out the possibility that the higher BCL3 protein levels in virally infected INA-6 cells compared to control cells might be the reason for the observed proapoptotic effect. Knock down of BCL3 by an siRNA approach did not show an effect on the survival of INA-6 cells. Thus, BCL-3 expression seems not to be essential for the viability of MM cell line INA-6. Richard et al. (1999) noted that enforced BCL3 expression could not account for the anti-apoptotic effect of IL-9 against glucocorticoid-induced apoptosis in T-cell lymphoma. Therefore, the cellular features determining whether BCL3 acts positively or negatively on the transcription of NF-kB-dependent anti-apoptotic genes remain to be identified.
Materials and methods
Cell culture and antibodies
Human MM cell lines (INA-6, XG-1, JK6-E, MM1.S) were maintained in RPMI 1640 medium containing 50 mM 2-mercaptoethanol. Human hepatocellular carcinoma cells (HepG2) were cultured in Dulbecco's modified Eagle's medium with F12 nutrient mixture (DMEM/F12). All media were supplemented with 10% fetal calf serum (FCS) and 100 U/ml of penicillin and streptomycin (all from Invitrogen, Karlsruhe, Germany). INA-6, JK6-E and XG-1 cells were maintained in the presence of 1 ng/ml IL-6. Recombinant human IL-6 was a gift from S Rose-John (Kiel, Germany). Antibodies against BCL3 (sc-185) and p50 (sc-7178) were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The anti-Stat3 serum (PA-ST3) and b-actin (Clone AC-74) antibody were from R&D Systems (Wiesbaden, Germany) and Sigma (Taufkirchen, Germany), respectively.
Real-time PCR
Total RNA was prepared using the RNeasy Mini Kit (Qiagen, Hilden, Germany). Real-time PCR was carried out using a LightCycler as described (Brocke-Heidrich et al., 2004) .
Immunoblotting Lysis was performed by heating 2 Â 10 6 cells in 100 ml sodium dodecyl sulfate (SDS) sample buffer (62.5 mM Tris-HCl pH 6.8, 2% w/v SDS, 10% glycerol, 50 mM DTT, 0.01% (w/v) bromophenol blue) for 5 min. After 2 min of microcentrifugation, 25 ml were analysed by SDS-polyacrylamide gel electrophoresis. Separated proteins were transferred to a polyvinyl difluoride membrane and detected by chemiluminescence.
ChIP
Experiments were performed according to the protocol provided with the ChIP assay kit from Upstate (Lake Placid, NY, USA).
INA-6 cells were either deprived of IL-6 for 12 h and restimulated for 0.5 and 1 h, or continuously cultured with IL-6. 2 Â 10 7 cells were used per experiment. Sonication was carried out four times for 15 s at 50% amplitude to yield an average DNA fragment size of 400 bp using the Sonoplus HD 70 (Bandelin, Berlin, Germany). The final DNA pellet was resuspended in 30 ml Tris-EDTA (TE). A measure of 3-5 ml of TE or input DNA were amplified in a 10 ml PCR reaction using primer pairs specific for HS3 (sense, 5 0 -CGCTTCCT CCAACCTTAACC -3 0 ; antisense, 5 0 -TGCCCAGTCCC TAACCTCTT -3 0 ) and HS4 (sense 5 0 -CATTCGAGGATG GAAGTTGG-3 0 , antisense, 5 0 -CAGGGTTAAGTGAGGG CAGA-3 0 ) and analysed on agarose gels. A b-actin and input control were included to demonstrate antibody specificity and equal amounts of starting material, respectively.
Plasmids
The construction of pSuper-siStat3 expressing siRNA against Stat3 was described previously (Holtick et al., 2005) . As control, a vector with a scrambled sequence (5 0 -ACACGTCC-GAACATACTAC-3 0 ) was similarly cloned giving pSuperscrambled.
pGL3 derivatives containing the BCL3 promoter either alone or together with enhancer regions HS3 or/and HS4, as well as corresponding TK reporter constructs were described previously (Ge et al., 2003) . Herein 'HS3/4' refers to plasmid Pr11E3 þ 4. HS3/4DkB site was obtained by using Pr11E3DkB as template. The XbaI-SalI fragment from HS3/4 was subcloned into pUC19. The XbaI-SacII fragment of Pr11E3DkB was amplified by PCR and ligated into the pUC19 derivative. The XbaI-SalI-DkB fragment was back-cloned into HS3/4 giving HS3/4DkB.
Mutations of the four putative Stat sites within HS3/4 were introduced by using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA, USA.). For that purpose, the HS3 þ 4 fragment was isolated from a bacteriophage genomic clone with Acc65I-NcoI, filled in with Klenow fragment, and cloned into the SalI site of pBC KS þ vector (Stratagene). For convenience of selection, in each case a novel restriction enzyme site was introduced. The following oligonucleotides and their complementary sequences were used (alterations are underlined): S1, GCTGGGGCTGAGACTAGTCCGGAAC GGCAGCGG; S2, AGACCTGTTACTGTACATCCGAG GGCTGGG; S3, CCGCGCGTTTATGGGCCCTCAGGC CTGGACGG; and S4, CAGGCCTGGACGGTGGATCC GAAATCATTCGCTG. After corroboration of mutations by sequencing, the four mutant forms HS3 þ 4 were digested with XhoI and SalI and were cloned into the plasmid Pr11 to generate HS3/4DS1, DS2, DS3 and DS4, respectively. HS3/4DS2-4 and HS3/4DS1-4 were constructed by introducing the S3 and S4 mutations simultaneously by inverse PCR. For that purpose, the XbaI-SalI fragment from HS3/4DS2 was subcloned into pBC KS þ , and the resulting plasmid served as template for the PCR using two back-to-back primers each carrying a mutation (S3, 5 0 -GGCCTGAGGGCCCATAAA CGCGCG-3 0 ; S4, 5 0 -TGGACGGTGGATCCGAAATCAT TCGCTGC-3 0 ). The AflII-SalI-DS2-4 fragment from the recircularized plasmid was transferred into HS3/4 and HS3/ 4DS1, giving HS3/4DS2-4 and HS3/4DS1-4, respectively.
The human ACT promoter comprising the region À359 to þ 25 relative to the transcription start site was subcloned from pha 1 -ACT-359CAT (Kordula et al., 1998) into pGL3-Basic (Promega, Mannheim, Germany).
For expression in INA-6 cells, FLAG-tagged BCL3 from pcDNA-BCL3 (provided by C Scheidereit, Berlin, Germany) was inserted into the lentiviral vector MLV-IRES-EGFP (Brocke-Heidrich et al., 2004) . BCL3 was released from pcDNA by digestion with HindIII (filled in) and XbaI and cloned into the vector after digestion with BamHI (filled in) and XbaI, yielding plasmid VI-BCL3.
Reporter gene assays of HepG2 cells
Transient transfections of HepG2 cells were performed in a 1:3 (v/v) mixture of DMEM/F12 and DMEM in six-well plates by using the calcium phosphate precipitation method (Mellon et al., 1981) . Precipitates contained 1 mg luciferase reporter, 1 mg b-galactosidase expression vector (pCH110) and sufficient empty vector to yield 3 mg total DNA. For assays with BCL3 expression, the indicated amount of plasmid VI-BCL3 was included. For expression of siRNA amount of HS3/4 luciferase reporter and pCH110 was reduced to 0.25 mg and mixed with 2.5 mg pSuper-siStat3, or pSuper-scrambled as control. Cells were incubated for about 6 h, rinsed and placed in medium containing 0.5% FCS. After 1 day, cells were stimulated with 10 ng/ml IL-6 for another 18 h and harvested 48 h posttransfection in 150 ml reporter lysis buffer (Promega). Luciferase and b-galactosidase activities were measured using kits from Promega and Roche (Mannheim, Germany), respectively. Luciferase values were normalized by transfection efficiency as measured by b-galactosidase. All data represent mean values7s.d. of three independent experiments.
Reporter gene assays and lentiviral infection of MM cells pSuper derivatives and reporter plasmids were introduced in XG-1 and INA-6 cells by electroporation as described by Chatterjee et al. (2004) . Briefly, cells were collected at 300 g and resuspended in RPMI medium without additives at a cell density of 1 Â 10 7 /ml. Electroporation of 500 ml cell suspension employed a Gene Pulser s II (BIO-RAD, Mu¨nchen, Germany) at settings of 950 mF and 280 V.
For immunoblot analysis of XG-1 cells, 1 mg pEGFP-N1 (Clontech, Mountain View, USA) and 19 mg pSuper-siStat3 or pSuper-scrambled were added. After electroporation, 4 Â 10 7 cells were combined per experiment and cultured in medium with 20% FCS and 1 ng/ml IL-6. After 48 h, cells were sorted using a FACS-Vantage (BD Biosciences, Heidelberg, Germany) on the basis of green fluorescence.
For reporter assays in INA-6 cells, 15 mg luciferase reporter and 5 mg pCH110 were added. Per experiment, 1 Â 10 7 cells were combined in medium supplemented as above. After 24 h, cells were washed, divided and cultured in the presence or absence of IL-6 for 18 h. Reporter activity was determined as above. Lentiviral infection was performed as described (Brocke-Heidrich et al., 2004) .
Apoptosis assay
Apoptosis was detected by flow cytometry using annexin V and 7-amino-actinomycin D staining as described recently (Brocke-Heidrich et al., 2004) .
